"10.1371_journal.pone.0030801","plos one","2012-02-23T00:00:00Z","Sara A Byron; Michael Gartside; Matthew A Powell; Candice L Wellens; Feng Gao; David G Mutch; Paul J Goodfellow; Pamela M Pollock","Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona, United States of America; Divisions of Gynecologic Oncology, Biostatistics and Endocrine Oncology, Siteman Cancer Center and Washington University School of Medicine, St. Louis, Missouri, United States of America","Conceived and designed the experiments: MAP DGM PJG PMP. Performed the experiments: SAB MG CLW. Analyzed the data: SAB MG CLW FG PJG PMP. Contributed reagents/materials/analysis tools: MAP FG DGM PJG PMP. Wrote the paper: SAB MAP PJG PMP. Critically reviewed, revised, and approved the final manuscript for submission: SAB MG MAP CLW FG DGM PJG PMP.","The authors have read the journals policy and have the following conflicts to declare: Matthew Powell - Honoraria from Speakers Bureau (Merck, Sanofi-Aventis, OrthoBiotech) and Consultant/Advisory Board (Eisai, Glaxo-Smith-Klein, Novartis, OrthoBiotech, Sanofi-Aventis, Genetech). Dr. Pollock and Dr. Goodfellow have filed two patents regarding the detection of FGFR2 mutations in endometrial cancer samples (20100111944, Method of Diagnosing, Classifying and Treating Endometrial Cancer and Precancer, filed 24 March 2008) as well as a second patent regarding utilizing FGFR2 mutations to predict increased risk of recurrence in endometrial cancer patients (WO2011009114, Method of assessing Endometrial Cancer risk, Filed July 2009) which is relevant to this manuscript. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","02","Sara A Byron","SAB",8,TRUE,4,3,6,4,TRUE,TRUE,FALSE,0,NA,FALSE
